Berotralstat received approval from the US Food and Drug Administration (FDA) on December 3, 2020.

Sobi submits biologics license application to the FDA for SEL-212, targeting chronic refractory gout treatment.

Setmelanotide received FDA approval on November 25, 2020. The approval was granted for the treatment of obesity caused by rare genetic disorders.

Tyra Biosciences has reported preclinical proof-of-concept findings for TYRA-300, an experimental orally administered FGFR3 selective inhibitor.

Naxitamab received accelerated approval from the U.S. Food and Drug Administration (FDA) on November 25, 2020.

Satellos Reveals Initial Data Indicating Muscle Recovery and Healing from SAT-3247 Treatment in Dog Model of Duchenne Muscular Dystrophy (DMD).

Casirivimab and Imdevimab received Emergency Use Authorization (EUA) from the FDA on November 21, 2020.

The U.S. FDA has granted approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), developed by Eli Lilly and Company.

Approved on November 20, 2020, it offers a vital treatment option for managing these rare genetic conditions.

Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.

Approved on October 14, 2020, it provides a crucial option for managing and treating Ebola virus disease.

7.1-7.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.